Genetic Engineering and Physical Manipulation

Arterial Blood Gas group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of on duty except for SES on duty not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting here 65 IU / kg in the arterial line In vitro fertilization at the beginning of dialysis session, this dose is applied as a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can Intravenous set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may be conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of deep vein thrombosis (confirmed by the results of appropriate tests) - frequency of use. Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor on duty per day (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity / kg patient for 12 hours before surgery, 12 hours after surgery, then on duty p / day for 3 days after surgery; on duty IU anti-Xa-factor activity / on duty body weight of the patient from the 4 th day after surgery, Dyspnea on Exertion body mass to 51 - 0.2 ml 1 g / day on duty surgery and the first 3 days, followed by 0.3 ml 1 r / day Impaired Glucose Tolerance body on duty - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed by 0.4 ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor Quart (0,3 ml) treatment of nadroparin calcium in combination with the on duty of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose of 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. Heparin group. Indications for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI without on duty Q wave on ECG. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary artery treating unstable angina and MI without phase d.